Drug intelligence / Profile preview

vaxigen Flu H5N8

Development stage: Unknown
Lead developer: CSL Seqirus
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

vaxigen Flu H5N8 is a recombinant veterinary vaccine developed by Avi-Mex (Laboratorios Avimex) for the immunization of poultry against Avian Influenza caused by the H5N8 subtype. The vaccine utilizes Avi-Mex's proprietary Vaxigen platform, which typically employs a recombinant viral vector (such as Newcastle Disease Virus) to express the hemagglutinin (HA) protein of the target influenza virus. This approach induces a robust and protective immune response in chickens and other poultry species, helping to prevent clinical disease and reduce viral shedding during outbreaks of highly pathogenic avian influenza (HPAI).

Brand names: vaxigen Flu H5N8
Other names: Vaxigen Flu H5N8-Avi-Mex-vaccine-biologic-Avian influenza (H5N8) in poultry

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on vaxigen Flu H5N8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vaxigen Flu H5N8.

Explore the full profile